ERGOMED

News

News


London, UK, 16 June 2017

Results of 2017 Annual General Meeting

London, UK –16 June 2017: Ergomed plc (LSE: ERGO) (‘Ergomed’ or ‘the Company’), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announces that all resolutions put to shareholders were duly passed at its Annual General Meeting held earlier today.

Resolutions 1 to 5 were passed on a show of hands. Details of proxy results were as follows:

 

Resolution

number

Votes for Votes against Abstentions
1 7,173,627 152,834 Nil
2 7,325,794 Nil 667
3 7,325,794 Nil 667
4 7,325,794 Nil 667
5 7,315,839 Nil 10,622

 

Details of voting results for resolutions 6 and 7 (including proxies) were as follows:

 

Resolution

number

Votes for Votes against Abstentions
6 24,118,915 4,235,625 13,622
7 24,118,915 4,235,625 13,622

 

The full text of all resolutions can be found in the Notice of Annual General Meeting on the

Company’s website www.ergomedplc.com

Enquiries:

 

Ergomed plc                                                                                      Tel: +44 (0) 1483 503205

Miroslav Reljanovic (Chief Executive Officer)

 

Stephen Stamp (Chief Financial Officer)

 

Numis Securities Limited                                                                 Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser) James Black (Joint Broker)

 

N+1 Singer                                                                                       Tel: +44 (0) 20 7496 3000

Alex Price (Joint Broker)

 

Consilium Strategic Communications – for UK enquiries                Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott / Ivar Milligan                  ergomed@consilium-comms.com

 

MC-Services – for Continental European enquiries                            Tel: +49 211 5292 5222

Anne Hennecke

 

About Ergomed

Ergomed plc is a profitable UK-based business providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 50 countries.

Ergomed provides clinical development, trial management and pharmacovigilance services to over 100 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.

Ergomed has a wide therapeutic focus, with a particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers  by its innovative Study Site Management  model  and  the  use  of  Study  Physician  Teams,  resulting  in  a  close relationship between Ergomed and the physicians involved in clinical trials.

As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed leverages its expertise and services in return for carried interest in the drugs under development. Lastly, Ergomed acquired a pipeline of proprietary development products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com.


|

Translate »